SCHEMBL459746

SCHEMBL459746

CCOCCNC(=O)CBr

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.42
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 2/20 0.39
NPC1 O15118 1/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
THRB P10828 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PCNA P12004 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18120313 0.96 MEN1 (0.44) EPHX2RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL15849987 0.85 ALDH1A1 (0.42) EPHX2RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL7547013 0.85 MEN1 (0.47) RAB9AALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL15849994 0.84 MEN1 (0.39) EPHX2RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL29067155 0.84 SMN1; SMN2 (0.40) EPHX2RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL24894030 0.84 MEN1 (0.44) EPHX2ALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL16949526 0.84 MEN1 (0.44) EPHX2ALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL10304153 0.83 MEN1 (0.56) EPHX2RAB9AALDH1A1SMN1; SMN2TSHR
SCHEMBL16853233 0.81 MEN1 (0.39) SMN1; SMN2TSHRMEN1KMT2AL3MBTL1
SCHEMBL9735108 0.81 EPHX2 (0.44) EPHX2RAB9AALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013103780-A1 COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA TRUSTEES OF BOSTON UNIVERSITY (US) 2013-07-11 WO claimed
US-20090324682-A1 Medical stent provided with inhibitors of atp synthesis INTERSTITIAL THERAPEUTICS (CH) 2009-12-31 US claimed
EP-1789030-A2 MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS Interstitial Therapeutics (CH) 2007-05-30 EP claimed
EP-1789107-A2 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS Interstitial Therapeutics (CH) 2007-05-30 EP claimed
WO-2006024488-A2 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO claimed
WO-2006024490-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO claimed
WO-2006024491-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO claimed
WO-2006024492-A2 MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO claimed
EP-4438734-A2 REPROGRAMMING OF CELLS TO A NEW FATE The Scripps Research Institute (US) 2024-10-02 EP disclosed
EP-3399026-B1 REPROGRAMMING OF CELLS TO A NEW FATE SCRIPPS RESEARCH INST (US) 2024-06-26 EP disclosed
US-20220280460-A1 METHODS AND COMPOSITIONS FOR STIMULATING EXOSOME SECRETION UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2022-09-08 US disclosed
US-20210189348-A1 REPROGRAMMING OF CELLS TO A NEW FATE THE SCRIPPS RESEARCH INSTITUTE 2021-06-24 US disclosed
WO-2021040999-A1 METHODS AND COMPOSITIONS FOR STIMULATING EXOSOME SECRETION UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-03-04 WO disclosed
US-10934528-B2 Reprogramming of cells to a new fate THE SCRIPPS RESEARCH INSTITUTE (US) 2021-03-02 US disclosed
EP-1789030-A2 MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS Interstitial Therapeutics (CH) 2007-05-30 EP disclosed
EP-1789107-A2 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS Interstitial Therapeutics (CH) 2007-05-30 EP disclosed
WO-2006024488-A2 MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO disclosed
WO-2006024490-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO disclosed
WO-2006024491-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO disclosed
WO-2006024492-A2 MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS INTERSTITIAL THERAPEUTICS (CH) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324682-A1 Medical stent provided with inhibitors of atp synthesis ATP5ME, ATP5F1A, ATP5MG EPHX2 2220/4885RAB9A 3291/4885ALDH1A1 3199/4885
US-10934528-B2 Reprogramming of cells to a new fate ALPG, POU5F1, POU2F1 EPHX2 972/4885RAB9A 1376/4885ALDH1A1 2103/4885
US-20210189348-A1 REPROGRAMMING OF CELLS TO A NEW FATE ALPG, POU5F1, POU2F1 EPHX2 972/4885RAB9A 1376/4885ALDH1A1 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.